Cancer chronotherapy: principles, applications, and perspectives (Q35030286)

5 August 2017

1 reference

title

Cancer chronotherapy: principles, applications, and perspectives. (English)

1 reference

5 August 2017

Marie-Christine Mormont

series ordinal

1

1 reference

PubMed ID

12491517

5 August 2017

Francis Levi

series ordinal

2

1 reference

PubMed ID

12491517

5 August 2017

language of work or name

English

0 references

publication date

1 January 2003

1 reference

5 August 2017

1 reference

5 August 2017

97

1 reference

5 August 2017

155-169

1 reference

5 August 2017

1

1 reference

Host circadian clock as a control point in tumor progression.

5 August 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11040

Spontaneous or imposed circadian changes in plasma concentrations of 5-fluorouracil coadministered with folinic acid and oxaliplatin: relationship with mucosal toxicity in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11040

Independent photoreceptive circadian clocks throughout Drosophila

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11040

7 January 2021

Mutagenesis and mapping of a mouse gene, Clock, essential for circadian behavior

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11040

7 January 2021

The genetic background of circadian and ultradian rhythm patterns of 17-hydroxycorticosteroids: a cross-twin study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11040

7 January 2021

Circadian oscillation of a mammalian homologue of the Drosophila period gene

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11040

7 January 2021

Central neural mechanisms in diurnal rhythm regulation and neuroendocrine responses to light

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11040

7 January 2021

Circadian Rhythms in Drinking Behavior and Locomotor Activity of Rats Are Eliminated by Hypothalamic Lesions

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11040

7 January 2021

Transplanted suprachiasmatic nucleus determines circadian period

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11040

7 January 2021

Circadian-system alterations during cancer processes: a review

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11040

7 January 2021

Circadian rhythms in DNA synthesis and mitosis in normal mice and in mice bearing the Lewis lung carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11040

7 January 2021

Liver cell control after discontinuation of DENA feeding in hepatocarcinogenesis.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11040

7 January 2021

Daily Variation of Body Temperature, Liver Catalase Activity, and Plasma Iron Concentration in Normal and Tumor-Bearing Rats

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11040

7 January 2021

Variation of growth rate of a rat tumour during a light-dark cycle: correlation with circadian fluctuations in tumour blood flow

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11040

7 January 2021

Mitotic Rhythms in Human Cancer, Reevaluated by Electronic Computer Programs—Evidence for Chronopathology2

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11040

7 January 2021

Circadian and ultradian cytokinetic rhythms of spontaneous human cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11040

7 January 2021

DNA cell cycle distribution and glutathione (GSH) content according to circadian stage in bone marrow of cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11040

7 January 2021

Decreased nocturnal plasma melatonin peak in patients with estrogen receptor positive breast cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11040

7 January 2021

Diminished pineal function coincides with disturbed circadian endocrine rhythmicity in untreated primary cancer patients. Consequence of premature aging or of tumor growth?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11040

7 January 2021

Non-invasive estimation of the circadian rhythm in serum cortisol in patients with ovarian or colorectal cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11040

7 January 2021

Rhythm alteration in patients with metastatic breast cancer and poor prognostic factors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11040

7 January 2021

Disruption of the circadian patterns of serum cortisol in breast and ovarian cancer patients: relationships with tumour marker antigens

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11040

7 January 2021

Diurnal cortisol rhythm as a predictor of breast cancer survival

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11040

7 January 2021

The difference between activity when in bed and out of bed. I. Healthy subjects and selected patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11040

7 January 2021

Contribution of the rest-activity circadian rhythm to quality of life in cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11040

7 January 2021

Circadian time dependence of murine tolerance for carboplatin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11040

7 January 2021

Circadian rhythm in tolerance of mice for the new anthracycline analog 4'-O-tetrahydropyranyl-adriamycin (THP)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11040

7 January 2021

Circadian changes in mitoxantrone toxicity in mice: relationship with plasma pharmacokinetics

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11040

7 January 2021

Tumor-based rhythms of anticancer efficacy in experimental models.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11040

7 January 2021

Circadian optimisation of irinotecan and oxaliplatin efficacy in mice with Glasgow osteosarcoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11040

7 January 2021

Pharmacologic modulation of reduced glutathione circadian rhythms with buthionine sulfoximine: relationship with cisplatin toxicity in mice

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11040

7 January 2021

Plasma 5-fluorouracil and alpha-fluoro-beta-alanin accumulation in lung cancer patients treated with continuous infusion of cisplatin and 5-fluorouracil

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11040

7 January 2021

Circadian rhythm of 5-fluorouracil population pharmacokinetics in patients with metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11040

7 January 2021

Circadian rhythm of cellular proliferation in the human rectal mucosa

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11040

7 January 2021

Sequential chemotherapy and circadian rhythm in human solid tumours. A randomised trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11040

7 January 2021

Maintenance chemotherapy for childhood acute lymphoblastic leukaemia: better in the evening

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11040

7 January 2021

Circadian timing of cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11040

7 January 2021

Chemotherapy of advanced ovarian cancer with 4'-O-tetrahydropyranyl doxorubicin and cisplatin: a randomized phase II trial with an evaluation of circadian timing and dose-intensity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11040

7 January 2021

Circadian-shaped infusions of floxuridine for progressive metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11040

7 January 2021

A phase I trial of 5-day chronomodulated infusion of 5-fluorouracil and 1-folinic acid in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11040

7 January 2021

Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11040

7 January 2021

Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11040

7 January 2021

A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11040

7 January 2021

Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11040

7 January 2021

Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11040

7 January 2021

Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil, and leucovorin in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11040

7 January 2021

A multicenter evaluation of intensified, ambulatory, chronomodulated chemotherapy with oxaliplatin, 5-fluorouracil, and leucovorin as initial treatment of patients with metastatic colorectal carcinoma. International Organization for Cancer Chronothe

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11040

7 January 2021

Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11040

7 January 2021

Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11040

7 January 2021

From circadian rhythms to cancer chronotherapeutics

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11040

7 January 2021

It's time for chronotherapy!

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11040

7 January 2021

Identifiers

DOI

10.1002/CNCR.11040

1 reference

5 August 2017

1 reference

PubMed ID

12491517